Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. sciencedirect.com

    More recently, MTBVAC vaccine efficacy was reapreaised in the context of the evolutionary genomics of M. tuberculosis, where MTBVAC variants constructed in clinical isolates belonging to lineages 2 (which includes Beijing strains) and 3 (L2 and L3) together with the original MTBVAC vaccine, derivative of L4, were compared against BCG in mouse ...
    Author:Carlos Martín, Dessislava Marinova, Nacho Aguiló, Jesús Gonzalo-AsensioPublished:2021
  2. sciencedirect.com

    Dec 1, 2023Tuberculosis (TB) remains a major global health burden, causing more than 10 million new cases and 1.6 million deaths each year. Currently, the only approved TB vaccine in use in humans, is the one hundred years old vaccine, BCG, an attenuated vaccine derived from an isolate of Mycobacterium bovis that causes TB in cattle. BCG shows a variable efficacy in preventing pulmonary forms of the ...
  3. Was this helpful?
  4. pubmed.ncbi.nlm.nih.gov

    MTBVAC, which contains the antigen repertoire of M. tuberculosis, is now poised to initiate Phase 3 efficacy trials in newborns in TB-endemic countries. BCG's efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life.
    Author:Carlos Martín, Dessislava Marinova, Nacho Aguiló, Jesús Gonzalo-AsensioPublished:2021
  5. pubmed.ncbi.nlm.nih.gov

    BCG shows a variable efficacy in preventing pulmonary forms of the disease in humans, so new vaccines are needed to help stop TB transmission. Among the 15 diverse TB vaccine candidates in clinical trials, MTBVAC is the only one based on rational attenuation of a human clinical isolate of Mycobacterium tuberculosis, which contains the largest ...
  6. pmc.ncbi.nlm.nih.gov

    The preclinical data with MTBVAC and SO2 provided a proof-of-concept to progress MTBVAC to first-in-human Phase 1 clinical evaluation. For this purpose, MTBVAC was developed and characterized as a freeze-dried vaccine product by the Spanish Biopharmaceutical company, Biofabri, in compliance with current Good Manufacturing Practices, fulfilling regulatory guidelines for assuring the quality ...
  7. Was this helpful?
  8. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC7117655

    Here we describe how MTBVAC, a new vaccine against tuberculosis based on a genetically modified form of the human pathogen Mycobacterium tuberculosis, that has shown similar safety profiles and improved protection than BCG in preclinical studies, is able to induce trained immunity in human cells and grant protection against a heterologous model ...
  9. pubmed.ncbi.nlm.nih.gov

    Here we show that MTBVAC, a live attenuated strain of Mycobacterium tuberculosis, safe and immunogenic against tuberculosis antigens in adults and newborns, is also able to generate trained immunity through the induction of glycolysis and glutaminolysis and the accumulation of histone methylation marks at the promoters of proinflammatory genes ...
  10. researchgate.net

    BCG's efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life.
  11. archbronconeumol.org

    Oct 5, 2023tuberculosis vaccine: MTBVAC MTBVAC has been designed and constructed with the aim of providing better protection than the current BCG against respira-tory forms of the disease. In its conception we have considered the experienceof100yearsofBCGuse,bothbeingliveattenuatedvac-cines, can be administered intradermally in a single dose and the
  12. thelancet.com

    Clearly, if MTBVAC is shown to offer better protection than the BCG vaccine against tuberculosis disease in efficacy trials, as suggested by preclinical studies, 19,27 the data from our trial will be important to support development of alternative diagnostic tests for M tuberculosis infection that are not cross-reactive with MTBVAC. For example ...
  13. Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX